Real-world data: nivolumab combo before lung cancer surgery shows promise in argentina
NCT ID NCT07141563
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study from Argentina looked at 70 patients with resectable non-small cell lung cancer who received nivolumab (Opdivo) plus chemotherapy before surgery. Researchers wanted to see how well this combination works in real-world practice, measuring how many patients had no cancer left after surgery. The study is observational, meaning it only reviewed past medical records, so it cannot prove the treatment caused the outcomes.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nivolumab (Opdivo) plus platinum-based chemotherapy
What this could lead to
If results are positive, this could support using this combination before surgery for lung cancer in real-world settings.
What could go wrong
This is a small, retrospective study (just 70 people) that looks back at past data, so it cannot prove cause and effect. Results may not apply to other populations.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Grupo Argentino Oncología Torácica (GAOT) - Asociación Argentina Oncología Clínica (AAOC)
Buenos Aires, C1426CPU, Argentina